| Literature DB >> 32895573 |
Mohamed Abdel-Mohsen1, Douglas Richman2, Robert F Siliciano3, Michel C Nussenzweig4, Bonnie J Howell5, Javier Martinez-Picado6,7,8, Nicolas Chomont9, Katharine J Bar10, Xu G Yu11,12, Mathias Lichterfeld11,12, Jose Alcami13, Daria Hazuda5, Frederic Bushman10, Janet D Siliciano3, Michael R Betts10, Adam M Spivak14, Vicente Planelles14, Beatrice H Hahn10, Davey M Smith2, Ya-Chi Ho15, Maria J Buzon13, Christian Gaebler4, Mirko Paiardini16,17, Qingsheng Li18, Jacob D Estes19, Thomas J Hope20, Jay Kostman21, Karam Mounzer21, Marina Caskey4, Lawrence Fox22, Ian Frank10, James L Riley10, Pablo Tebas10, Luis J Montaner23.
Abstract
Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will require a consensus on how best to measure the numbers of persistently infected cells with the potential to cause viral rebound after antiretroviral-therapy cessation in assessing the results of cure-directed strategies in vivo. Current measurements assess various aspects of the HIV provirus and its functionality and produce divergent results. Here, we provide recommendations from the BEAT-HIV Martin Delaney Collaboratory on which viral measurements should be prioritized in HIV-cure-directed clinical trials.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32895573 PMCID： PMC7703694 DOI： 10.1038/s41591-020-1022-1
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 87.241